Abstract
We investigated the antimicrobial activity and clinical efficacy of pazufloxacin (PZFX), a new fluoroquinolone, in urinary tract infections. The antimicrobial activity of PZFX against 270 clinically isolated of 9 species from patients with urinary tract infections (UTIs) was compared with that of norfloxacin, ofloxacin, tosufloxacin and ciprofloxacin. PZFX showed potent antimicrobial activity against gramnegative bacteria. In the most cases, the MICs of PZFX were lower or equal to those of the reference drugs. Five patients with complicated urinary tract infections were treated with PZFX, and clinical efficacy was evaluated according to the criteria proposed by the Japanese UTI Committee. The overall efficacy rate was 80%. Bacteriologically, 4 of 5 strains were eradicated in 5 patients with complicated UTI. The only adverse reaction observed mild rash in one case. Slight abnormal laboratory findings were observed in one case.
We concluded that PZFX was an effective and safe drug for the treatment of urinary tract infections.
